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respectively. Within a budget of 10 million RUR the number of
patients at European LDL-C goal at 1 year is: 558 on Crestor,
361 on Vasilip, 385 on Atoris and 394 on Tulip. CONCLU-
SION: Based on the equi-effective dose of statins CRESTOR is
shown to be cost-effective compared to atorvastatin and simvas-
tatin even at low generic prices across all value metrics analysed.
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THE ANALYSIS OF HEALTH AND ECONOMIC BENEFITS
ASTHE CONSEQUENCE OFTHE REALIZATION
CARDIOVASCULAR SYSTEM DISEASES PREVENTION
PROGRAMME AMONGTHE CHILDREN ANDYOUTH OF
SCHOOL AGE IN POLAND
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OBJECTIVES: The purpose of this study was to evaluate health
and economic beneﬁts, throughout the country, as the conse-
quence of the realization cardiovascular system diseases preven-
tion programme among the children and youth of school age in
Poland. METHODS: This was a health and an economic evalu-
ation using a simulation model based on 10,000 subjects. The
frequency of incidence of cardiovascular system diseases was
estimated using data from the Polish epidemiological trials pro-
grams and statistical yearbook. Costs of cardiovascular system
diseases treatment were derived from medical services catalogue
of The National Health Fund (NFZ). The effectiveness of pre-
ventive programmes was extracted from the INTERHEART
study and other published sources. RESULTS: Correctly con-
structed and conducted prevention programme of cardiovascular
system diseases among the children and youth of school age in
Poland could reduce about 70% lipid disorders, 50% obesity,
50% arterial hypertension, 8% heart attack, 5% the diabetes
mellitus type 2, and about 4% the cerebrovascular incident in
adult life of the beneﬁciaries. The indirect results of prevention
are the extending of life-span and the improvement of health
quality of individuals as well as their families, the improvement
of epidemiological situation and measurable ﬁnancial proﬁt
throughout the country because of dangerous and chronic health
complications prevention as well as lack of limitations of ability
to work. CONCLUSION: The cost of analysed preventive pro-
gramme of cardiovascular system diseases is about 15 times
smaller than health care costs of these diseases.
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OBJECTIVES: To perform a health technology assessment
(HTA) commissioned by the German Federal Ministry of Health
on coronary fractional ﬂow reserve (FFR) to guide the decision
on coronary stenting in patients with suspected mild coronary
artery disease (CAD). METHODS: We performed a systematic
literature search to identify clinical and economic studies on
FFR-guided strategies. A meta-analysis on the diagnostic value of
FFR and a review on economic evaluations were done. We devel-
oped a decision-analytic Coronary Artery Disease Outcome
Model (CADOM) for the German health care context. Patients
with angiographically suspected CAD without conﬁrmed diag-
nosis were modeled in subgroups for age and gender (basecase:
60-year old man). Model parameters were derived from German
databases and the published literature. We adopted the societal
perspective, used a life-time horizon, and discounted costs and
effects by 5% per year. RESULTS: We identiﬁed 10 diagnostic
accuracy studies, 1 multicenter randomized clinical trial (RCT)
for efﬁcacy, and 1 decision-analytic cost-effectiveness study (US
context). Pooled sensitivity and speciﬁcity of FFR was 81.7%
(95%CI: 77.0–85.7%) and 78.7% (95%CI: 74.3–82.7%),
respectively. Few studies used a sufﬁcient goldstandard. The RCT
investigated the efﬁcacy of a FFR-based treatment strategy and
showed advantages for patients in terms of major adverse cardiac
events and freedom from angina. The cost-effectiveness study
showed the FFR-based strategy being cost-saving in the US health
care system. Results from German CADOM indicated a gain in
(quality-adjusted) life-expectancy for the FFR-guided strategy
compared to universal coronary intervention in all patients. The
base-case discounted incremental cost-effectiveness ratio was
Euro 16,000 per QALY gained. Uni- and multivariate sensitivity
analyses showed robust results. CONCLUSION: This HTA sug-
gests that FFR-guided treatment results in clinical beneﬁts for
patients with suspected CAD and should be cost-effective in the
German context. FFR should be implemented in routine clinical
decision making in patients with suspected CAD.
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OBJECTIVES: The phenomena of response-shift has recently
entered the PRO literature and provided new insight how change
scores in PRO measures such as HRQL-instruments can be inter-
preted. Methods have been provided to investigate the 3 types of
response-shift: recalibration, reconceptualization and reprioriti-
zation. The aim of this study was to investigate to what extend
response-shift occurs in individualized vs. disease-speciﬁc
HRQL-instruments and how it can be captured. METHODS: In
a prospective longitudinal study 100 patients with angiographi-
cally documented coronary artery disease were approached at 2
time points (hospital-baseline and 6 month-follow-up) with an
individualized QoL-instrument (Schedule for the Evaluation of
Individualized Quality of Life; SEIQOL) and a disease-speciﬁc
HRQL-instrument (MacNew Heart Disease Quality of Life
Questionnaire; MacNew). The SEIQoL is constructed allowing
capturing two aspects of response-shift: reconceptualization
(cues) and reprioritization (weights). In addition the “Then-Test”
was applied to the MacNew at 6 month-follow-up to capture
recalibration. RESULTS: Informed consent was given by 64
patients (61+/-7.5 years, 28.1% female, main symptom: 71.9%
angina) and all patients were treated with percutaneous coronary
interventions. 71.9% returned the six-month follow-up. Indi-
vidualized QoL (SEIQoL-Index) did not improve over the 6
month-period (t0: 65.8+/-25.5; t1: 67.8+/-20.5, p = ns), in addi-
tion 25% of the participants showed response-shift effects of
reconceptualization in at least one cue of the SEIQoL. No sig-
niﬁcant change in SEIQoL cue-weights occurred. Disease-speciﬁc
HRQL scores changed signiﬁcantly over time (t0: 4.7+/-1.2, t1:
5.3+/-1.1, p = 0.004); and no recalibration occurred (t0-then-
test: 4.6+/-1.4, p = 0.418). CONCLUSION: This prospective
study investigating the effects of percutaneous coronary interven-
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tions highlighted that response-shift effects may be a result of the
instruments used. Individualized (generic) QoL -instruments can
be prone to response-shift effects due to their conceptualization
addressing a broad range of life aspects. In contrast, disease-
speciﬁc PRO measures focusing on speciﬁc aspects of disease are
less affected by response-shift phenomena.
CARDIOVASCULAR DISEASE—
Patient Reported Outcomes
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OBJECTIVES: According to international surveys, half of the
subjects with indications for statin therapy are treated and half
the treated subjects is still adherent after six month from starting
therapy. Poor adherence to statin therapy is the main factor of
cardiovascular prevention failure and health care costs increase.
Unfortunately, tools to support stakeholders in monitoring
current medical practice are unavailable. The aim of our work
was to perform a population-based retrospective analysis to
evaluate the characteristics of patients treated with statins and
their adherence to treatment through the linkage of administra-
tive databases of the LHS of Ferrara (approximately 350,000
beneﬁciaries). METHODS: All subjects aged >18 years receiving
at least a prescription for statins between January 1st, 2004 and
June 31st, 2005 were enrolled. In each subject we recorded age,
sex, concurrent chronic therapy, previous hospital admissions
and, starting from the ﬁrst prescription, a treatment proﬁle in the
following 6 months. Adherent subjects were deﬁned as having a
PDD-standardized (mean daily dose/PDD) >0.8. The pharmaco-
logical patterns were compared among three periods lasting 6
months each. RESULTS: Treated subjects decreased from 20,445
and 20.221 of the ﬁrst two periods to 17,756 of the third period
mainly for reduction of newly treated subjects (from 5,108 and
4342 to 3,688). Newly treated in the third period were more
frequently male, older and showed a higher prevalence of con-
current drug treatments and of previous cardiovascular hospital-
izations. Adherent subjects increased from 29,7% and 31.9% in
ﬁrst two periods to 45.4% in third period (OR 1648, CI 1.579–
1.721, p < 0.001). CONCLUSION: Poor adherence was associ-
ated with younger age, lower prevalence of concurrent drug
treatments and of previous cardiovascular hospitalizations.
Adequate systems are required to monitor and assess actual
practice, to highlight and size critical areas, to account stake-
holders for practice improvement through adherence to standard
rather than for cost containment.
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OBJECTIVES: The National Cholesterol Education Program
ATP III (ATPIII) guidelines notes that patient persistence to lipid-
lowering therapy is suboptimal. Persistence is especially impor-
tant because patients with hyperlipidemia typically require
long-term treatment. ATPIII further notes that adherence appears
to be unrelated to sex, age, ethnicity, or socioeconomics. Given
that women and racial minorities are less likely to achieve ATPIII
lipid goals, we sought to retrospectively examine the relationship
between speciﬁc demographics and the likelihood of discontinu-
ing antilipidemic medications. METHODS: Retrospective claims
analysis of Florida Medicaid adults (age18 years) who initiated
antilipidemics during 1997–2006, and who had 1 year of data
prior to, and 3 years of data following, their ﬁrst antilipidemic
claim. Premature discontinuation was deﬁned as no antilipidemic
claim for at least 6 months during the 3 year follow-up. Chi-
square examined categorical variables and Cox proportional
hazard examined demographic (sex, age, race/ethnicity) predic-
tors of discontinuation. RESULTS: Of 75,726 patients initiating
antilipidemics, most (68.8%; n = 52,085) were female and age
50 years (75.7%; n = 57,333); 42.7%, (N = 32,350) were
White, 18.5% (n = 14,015) Black, 9.5% (n = 7,163) Hispanic,
and 29.3% (n = 22,198) other races/ethnicities. Hispanics were
45%, other races/ethnicities 30%, and Blacks 7% more likely
to discontinue treatment (all p < 0.0001) than Whites. Younger
patients (<50 years) were 18% more likely to discontinue treat-
ment than older (>70 years) patients (p < 0.0001), and females
were 8% more likely to discontinue treatment than males
(p < 0.0001). CONCLUSION: Compared to ATPIII, which
reports that antilipidemic persistence is unrelated to demograph-
ics, we found antilipidemic persistence to be signiﬁcantly associ-
ated with patient sex, age, and race/ethnicity. However, our
results are consistent with those of other recent retrospective
studies that report a signiﬁcant relationship between demograph-
ics and adherence to lipid-lowering therapy. Poor persistence
may, in part, explain lower rates of achieving ATPIII lipid goals
seen among women and racial/ethnic minorities.
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OBJECTIVES: Chronic disease therapies have to be taken for
long periods, usually indeﬁnitely; hence the risk of discontinua-
tion is often high. Low compliance/persistence may compromise
the potential beneﬁts of treatment. The purpose of this study was
to investigate patients’ adherence and persistence to therapy with
hypolipemic medications using a large administrative database.
METHODS: We used the Regione Lombardia Health Service
(RLHS) administrative databases, which contain information on
a population of >9 millions individuals with universal health care
and pharmaceutical coverage. The study population included
individuals with at least one prescription of a hypolipemic agent
during the year 2003 and who were enrolled in the RLHS in the
year 2003. Persistence and adherence was evaluated with the
medication possession ratio (MPR), calculated as the ratio
between the number of pills dispensed during the study period
and the number of days of observation. MPR was estimated for
individuals who ﬁlled their ﬁrst prescription in the year before 31
October 2003. RESULTS: Out of a population of 9,108,645
members, 560,737 (6.2%) received at least one prescription of a
study drug. Frequency of use increased from 0.7% in subjects
with age <40 years to 18.4% in subjects age 70–79 y.o. A total of
16.2% of subjects received one or two packs during the study
period, the median number of packs prescribed was 14, and
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